Our CRISPR models using EGFR mutant lung cancer cell lines, enabled precise evaluation of the biology and drug resistance as a result of a concurrent fusion oncogene which would not have been possible using conventional simple Ba/F3 models. This evidence concerns the gene EGFR and lung carcinoma.